ArticleJournal of translational medicine2026
Personalized therapeutic platform: organoid models for hepatic malignancies.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPatient responses to therapeutic agents in hepatic malignancies are highly variable, yet the field lacks robust in vitro models for predicting individual drug responsiveness. Patient-derived organoids (PDOs) that faithfully recapitulate the biological characteristics of parental tumors offer a promising platform for personalized drug testing.
methodsWe established PDOs from fresh tumor tissues of 29 patients with hepatic malignancies, achieving a success rate of 79.31% (23/29). Histological staining confirmed high morphological and phenotypic consistency between PDOs and original tumor tissues. Drug sensitivity testing was performed using a panel of standard-of-care therapeutics, and model stability was assessed through serial passaging and cryopreservation. Clinical correlation was evaluated by comparing PDO-predicted sensitivity with observed treatment responses in 16 patients followed prospectively.
resultsThe established PDOs maintained structural and functional fidelity to parental tumors and demonstrated reproducible drug sensitivity profiles across serial passaging and cryopreservation. In a prospective clinical validation, patients whose treatment matched PDO-predicted sensitive agents showed significantly improved objective response rate (ORR: 36.36%, 95% CI: 10.93-69.21) and disease control rate (DCR: 90.91%, 95% CI: 58.72-99.77), compared to those receiving PDO-predicted resistant therapies (ORR: 0%, DCR: 20%).
conclusionThis study establishes a robust and clinically validated PDO platform for hepatic malignancies that accurately predicts patient-specific drug responses. The model demonstrates high reproducibility and stability, supporting its utility for guiding personalized therapy selection and improving outcomes in patients with liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.